Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00275548 · ClinicalTrials.gov registry record · Phase 4
Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT00275548: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT00275548 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00275548, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
The study is being done to study the impact of prophylactic administration of antiviral therapy as compared to initiation of antiviral therapy at the time of clinical recurrence of hepatitis C infection in liver transplant recipients.
Interventions
- DRUG Copegus
- DRUG Pegasys
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-07 |
| Est. Completion | 2009-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00275548
The ClinicalTrials.gov registry entry for NCT00275548 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Copegus is the first listed.
NCT00275548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00275548 about?
NCT00275548 is a clinical study titled "Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C". The study is being done to study the impact of prophylactic administration of antiviral therapy as compared to initiation of antiviral therapy at the time of clinical recurrence of hepatitis C infection in liver transplant recipients.
What is the current status of trial NCT00275548?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2004-07. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00275548?
The interventions under investigation include: Copegus (DRUG), Pegasys (DRUG).
Who is sponsoring clinical trial NCT00275548?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.